恒瑞医药：子公司恒格列净瑞格列汀二甲双胍缓释片获批上市

Core Viewpoint - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the launch of its oral hypoglycemic drug, HR20031, which is the first self-developed fixed-dose combination of three oral hypoglycemic agents in China [1] Company Summary - The approved product, HR20031, is a combination of empagliflozin, linagliptin, and metformin extended-release tablets [1] - It is indicated for adult patients with type 2 diabetes who have inadequate blood sugar control with metformin hydrochloride, in conjunction with diet and exercise [1] - This marks a significant milestone as there are currently no similar products approved for sale in the domestic market [1]